
We are working toward a world free of #psoriaticdisease by supporting research, education, and advocating for the needs of our community. #NPFPro
Alexandria, VA
Joined September 2023
- Tweets192
- Following66
- Followers71
- Likes68
New guidance for TB testing and IL-17/IL-23 inhibitors in psoriasis care. NPF partnered with MJH Life Sciences to bring together experts Joseph Merola, M.D., and Andrew Blauvelt, M.D., for a special report series on @HCPLiveNews
🎥 Watch the series: hcplive.com/sap-partner/nati…
Are your psoriasis treatments still working for you? Learn when it may be time to consider options beyond topical therapies and how to start the conversation with your healthcare team.
🔗 education.webmd.com/viewarti…
mdsc.pe/4y1aG4w
New Pro Podcast! Dermatologist Dr. Ron Prussick and cardiologist Dr. Brittany Weber discuss the emerging role of GLP-1 receptor agonists in the management of patients with psoriasis.
psoriasis.org/cme-library/ad…
This podcast is supported in part by Lilly.
Join our reimagined NPF Professional Membership program for trusted clinical resources, patient ed tools, networking, and to elevate your visibility in the field.
Be part of a community dedicated to advancing psoriatic disease care and research: psoriasis.org/promember
Thanks for posting this and sharing the link to our NPF Medical Board primer on GLP-1s and psoriasis, @EricTopol
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review | Dermatology | JAMA Dermatology | JAMA Network
Expanded benefits reported today for GLP-1 therapy @JAMADerm
Extragenital lichen sclerosus
jamanetwork.com/journals/jam…
Potential for psoriasis, a review of evidence
jamanetwork.com/journals/jam…
NPF Grant Applications are OPEN! Don’t miss out on these opportunities! We have opportunities available ranging from early-career researchers, to discovery or translational research, and more! Learn more today: psoriasis.org/available-fund….
Happening now, Hall F1! The NPF was successful in helping establish a PsA component to the fNIH AMP/AIM program. In fact, may be better described as “wildly successful.” The possibilities with spatial mutlti-omics seem nearly endless (Abstract 2233: ow.ly/E3hF50XhMBN).
At 10:15! NPF supported research that our CSMO consistently calls “jaw dropping.” Join Dr. Garcia-Hernandez’s presentation on creating mouse models of human PsD endotypes, #1753: Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model in W190A-B. #ACR25
Inspiring stories from our #psoriaticarthritis community are everywhere! Hear former NPF Board member, Kathleen Gallant, share her journey at 8:45 am in W192A-C. #ACR25
Explore sex differences in psoriatic disease. #ACR25 posters 1714: Perimenopause links to higher psoriatic arthritis activity; 0873: Deucravacitinib’s impact on sex-specific proteomic profiles in active psoriatic arthritis. Both presented TODAY by Lihi Eder, MD, PhD
While you’re thinking about your recruitment messages at Dr. Kearney’s Poster, did you know that the NPF MyStudies program (psoriasis.org/npf-mystudies-…) can help find patients interested in clinical research and located in your community? #ACR25
NPF alums' #ACR25 poster presentations getting to the heart of systemic inflammation consequences. See what we did there? Abstract 0522 from Lihi Eder on arrhythmias in PsA and 0546 on comorbidity groupings from Dr. Karmacharya are a great place to learn more. Now-Hall F1
1030am, Hall F1! NPF is proud to collaborate with CorEvitas on psoriatic disease registries. Check out real-world data about persistence of therapeutic agents (Abstracts 0362, 0579, 0578), & the therapeutic benefit of TYK2 on PsA (0455). #ACR25
The growing field of biomarkers for PsA is revolutionary. Take a look at what’s possible in today’s clinical trials - Abstract 0590 features technologies aligned with the NPF’s investment in PsA diagnostics. Presentations start at 10:30am, Hall F1 #ACR25
Tremfya® has just been approved for the treatment of children who are 6 years and older, and live with moderate to severe plaque psoriasis. This new indication marks the first and only (IL) - 23 inhibitor available to the pediatric population. Learn more🔗psoriasis.org/advance/tremfy…
Happy #InternationalPodcastDay! We are proud to bring you stories, #treatment updates, guidance on managing #psoriaticdisease, and so much more with #PsoundBytesCME for providers treating psoriatic disease.
Listen and learn: ow.ly/RUOy50JqYTn
TODAY is Generalized Pustular Psoriasis (GPP) Awareness Day, a day to shine a light on a rare and serious form of psoriasis. Help spread the word!
Learn more and explore our full GPP Resource Center ⬇️ psoriasis.org/gpp-toolkit
NPFPro retweeted
This year’s @NPF Commit to Cure gala raised more than 🎉$1.5 million🎉 for psoriatic research, breaking past fundraising records.
Honorees this year included @GoHealio | Dermatology Chief Medical Editor Joel M. Gelfand, MD.
Read more ⬇️
healio.com/news/dermatology/…
@leahmcchoward
New Psound Bytes Pro episode is out! Hear from Dr. Mark Lebwohl, M.D. and Dr. Jason Hawkes, M.D., M.S. discuss the intersection of obesity, psoriasis, and GLP-1s.
psoriasis.org/cme-library/gl…











